[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346164-105":59,"doc-detail-346164-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ai-genomics-synergy-for-drug-repurposing-in-breast-cancer-an-interpretability-driven-framework","AI-genomics synergy for drug repurposing in breast cancer - an interpretability-driven framework","","Breast cancer’s genomic heterogeneity makes drug discovery difficult yet supports drug repurposing as a pragmatic, cost-effective way to expand therapeutic options. Multi-omics integration with machine learning and deep learning can uncover latent gene–drug–disease relationships and predict responses, but many AI pipelines lack interpretability. This Review analyzes interpretability-focused computational approaches and proposes an integrated AI-Genomics framework that links interpretability, mechanistic validation, and clinical translation for more transparent, actionable precision oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ai-genomics-synergy-for-drug-repurposing-in-breast-cancer-an-interpretability-driven-framework/346164/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ai-genomics-synergy-for-drug-repurposing-in-breast-cancer-an-interpretability-driven-framework/346164.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is drug repurposing especially appealing for breast cancer?","Question",{"text":112,"@type":113},"Breast cancer’s molecular heterogeneity complicates conventional drug discovery and can limit benefit. Repurposing provides a pragmatic, cost-effective way to expand options by finding new indications for approved or investigational drugs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitation affects many AI-driven drug repurposing pipelines?",{"text":117,"@type":113},"Many use black-box models that deliver strong predictions without revealing underlying biological mechanisms. This reduces clinical trust and slows translational uptake.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the interpretability-driven framework aim to achieve?",{"text":121,"@type":113},"It links interpretability, mechanistic validation, and clinical translation, using subtype-aware priorities to move computationally predicted candidates toward experimental and clinical testing in a more transparent manner.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346164,1790870803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","npj | genomic medicine Review  \n\n| Published in partnership with CEGMR, King Abdulaziz University |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41525-026-00578-9](https://doi.org/10.1038/s41525-026-00578-9) |  |  |\n| AI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework\u003Cbr> Check for updates |  |  |\n| Rahaf M. Ahmad1, Salahdein Aburuz2, Bassam R. Ali1,3  & Noura AlDhaheri1,3  |  |  |\n| Breast cancer’s genomic heterogeneity complicates drug discovery, making repurposing an attractive but challenging strategy. Advances in artiﬁcial intelligence now enable integration of multi-omics data to reveal drug–gene–disease relationships and generate subtype-speciﬁc repurposing hypotheses. In this Review, we examine AI-driven computational approaches from signature-based to multi-modal frameworks and propose an integrated interpretability-driven framework linking mechanistic validation with clinical translation toward more transparent and actionable precision oncology. |  |  |\n| BC (Breast cancer) is the most prevalent malignancy among women worldwide, representing the second leading cause of cancer-related death, with an estimated 2.3 million new cases of BC and 670,000 deaths recorded in 20221. Despite remarkable progress in genomics and therapeutics, BC continues to pose major clinical challenges due to its profound molecular heterogeneity, spanning luminal, HER2-enriched, and triple-negative subtypes. This biological diversity underlies differential therapeutic response, drug resistance, and variable patient outcomes, necessitating strategies that are both biologically informed and adaptable to evolving disease landscapes2,3.\u003Cbr>Traditional drug discovery remains slow, costly, and characterized by high attrition rates, often yielding limited beneﬁts for genomically diverse cancers such as TNBC (triple-negative breast cancer). Consequently, drug repurposing, the systematic identiﬁcation of new indications for approved or investigational drugs, has emerged as a pragmatic and cost-effective approach to expand therapeutic options. The growing availability of multiomics data and functional genomics resources now provides a foundation for repurposing existing compounds in a biologically rational manner4,5.\u003Cbr>Parallel advances in AI (artiﬁcial intelligence) have transformed the capacity to interrogate these complex datasets. Machine learning and deep learning methods can integrate multi-omics, pharmacologic, and clinical information to reveal latent gene–drug–disease relationships, identify biomarkers, and predict therapeutic responses. Extending these capabilities to drug repurposing promises to accelerate the discovery of candidate therapies and enable precision medicine at scale6,7.\u003Cbr>Yet, most AI-driven repurposing pipelines remain limited by a lack of interpretability. Black box models often yield statistically powerful predictions without revealing the underlying biological mechanisms, limiting clinical trust and translational uptake. In a disease where treatment | decisions are intimately tied to mechanistic understanding of genomic alterations, interpretability becomes indispensable. Connecting algorithmic predictions with pathway-level insights, actionable targets, and subtypespeciﬁc vulnerabilities is essential for responsible clinical deployment8.\u003Cbr>In this Review, we examine the intersection of AI, genomics, and drug repurposing in BC through the lens of interpretability. We summarize recent advances in multi-omics integration, outline computational strategies for repurposing, and highlight how interpretable models can bridge the gap between algorithmic prediction and biological mechanism. Finally, we propose an integrative AI-Genomics framework that links interpretability, mechanistic validation, and clinical translation, toward more transparent and actionable precision oncology. Unlike previous reviews that survey computational methods in isolation, the integrated framework ","cbCaif7CJRypEeoI","https://ap.wps.com/l/cbCaif7CJRypEeoI","pdf",742693,"English","# Literature Review and Knowledge Gaps\n## Genomic landscape of breast cancer\n## Pathway from Algorithm to Clinic for AI-driven drug repurposing in BC","[{\"question\":\"Why is drug repurposing especially appealing for breast cancer?\",\"answer\":\"Breast cancer’s molecular heterogeneity complicates conventional drug discovery and can limit benefit. Repurposing provides a pragmatic, cost-effective way to expand options by finding new indications for approved or investigational drugs.\"},{\"question\":\"What limitation affects many AI-driven drug repurposing pipelines?\",\"answer\":\"Many use black-box models that deliver strong predictions without revealing underlying biological mechanisms. This reduces clinical trust and slows translational uptake.\"},{\"question\":\"What does the interpretability-driven framework aim to achieve?\",\"answer\":\"It links interpretability, mechanistic validation, and clinical translation, using subtype-aware priorities to move computationally predicted candidates toward experimental and clinical testing in a more transparent manner.\"}]","AI-genomics synergy for drug repurposing in breast cancer - an interpretability-driven framework | PDF",1790060353,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e17d90cd9a7a1e59cca94435835b251a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74104c76bd1f6c66a842e0ccf1d3a38c.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd2feb81d57784daf605d316b1cb08ec.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1d169d68c2d6f4be1766f219a0c8f35.webp",980,1301]